Cabotegravir

Drug Profile

Cabotegravir

Alternative Names: 1265744; 744 LA Injection; 744 Tablet; Cabotegravir long acting; Cabotegravir sodium; GSK-1265744; GSK-1265744A; GSK-1265744B; GSK-744; GSK-744-LA; GSK1265744 LAP; S-265744; S-265744B; S/GSK-1265744; S/GSK1265744 LAP

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shionogi - GlaxoSmithKline (JV)
  • Developer Gilead Sciences; National Institute of Allergy and Infectious Diseases; ViiV Healthcare
  • Class Antiretrovirals; Fluorobenzenes; Oxazoles; Pyrazines; Pyridones; Small molecules
  • Mechanism of Action HIV integrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections(In volunteers) in United Kingdom (PO, Tablet)
  • 18 Sep 2017 Phase-III clinical trials in HIV infections (Combination therapy) in Spain (PO) (EudraCT2017-002946-62)
  • 06 Jun 2017 ViiV Healthcare initiates enrolment in a phase I pharmacokinetic trial in Healthy volunteers in United kingdom (NCT03149848)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top